Nanoparticles may pinpoint, and ultimately, destroy breast tumors

Newly developed silica nanospheres may perform as ultrasound contrast markers and make tumors more visible to surgeons during breast lumpectomy, according to a team from University of California, San Diego (UCSD).

Although breast-conserving surgery is an appealing option for some women with breast cancer, it can be difficult for surgeons to precisely localize and then remove the entire tumor. Up to 25 percent of lumpectomies require re-excision.

The UCSD researchers, who have developed a method to tag tumors that might reduce the need for follow-up surgeries, presented their work at the AVS Symposium and Exhibition in Tampa, Fla.

Andrew Kummel, PhD, a chemical physicist from UCSD, and colleagues have developed implantable, iron-doped silica nanospheres. The gas-filled nanoparticles help surgeons visualize tumors via contrast-enhanced ultrasound and may increase surgical precision, according to a press release.

Ultimately, the nanoparticles may perform double duty. “We are using these particles for two applications. In the short term, we are injecting them into breast tumors to enable surgeons to halve the number of second surgeries by readily locating the tumors in the operating room with low-power ultrasound imaging. In the long term, we want to inject the particles intravenously, have them stick to the tumors and then ablate the tumors … with high-intensity focused ultrasound,” said Kummel in the release. 

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.